Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

'Groundbreaking Option' Approved for Rectal Cancer

(MedPage Today) -- The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The approval allows use in stage II/III patients with...

'Groundbreaking Option' Approved for Rectal Cancer

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Monday 19 October →